UCB overview

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa PR Newswire ATLANTA, May 23, 2024 BE HEARD I and BE HEARD II are the first Phase 3 trials to evaluate the efficacy and safety of an IL-17A and IL–17F inhibitor, BIMZELX ® (bimekizumab-bkzx), in the treatment of adult patients with moderate-to-severe hidradenitis suppurativa ATLANTA , May 23, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today...

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire ATLANTA, April 12, 2024 Diverse and patient-focused data set comprises 17 abstracts including one oral presentation Features new data analyses for UCB's generalized myasthenia gravis (gMG) treatments, including post hoc and open-label extension results from the pivotal Phase 3 MycarinG study and additional Interim Analyses of RAISE-XT for the...

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire ATLANTA, April 10, 2024 Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach people of all ages, races, and genders, including those most impacted by HS Co-created with people living with HS and dermatologists, the educational campaign features a broad range of tailored...

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations PR Newswire ATLANTA, April 4, 2024 Application in moderate-to-severe hidradenitis suppurativa based on results from two Phase 3 studies where BIMZELX ® (bimekizumab-bkzx) showed clinically meaningful improvements vs. placebo at Week 16 which were sustained to Week 48 Application for the additional BIMZELX 2mL device...

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis PR Newswire ATLANTA, March 9, 2024 Late-breaking platform presentation showed that BIMZELX ® (bimekizumab-bkzx) rapidly achieved and maintained high rates of clinical and health-related quality-of-life responses through four years; six out of ten patients achieved complete skin clearance at Year 4 Responder-analyses demonstrated that...

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count PR Newswire ATLANTA, March 8, 2024 Patients treated with BIMZELX ® (bimekizumab-bkzx) demonstrated clinically meaningful improvements in skin pain up to 48 weeks, across various assessed outcomes At Week 16, patients treated with BIMZELX demonstrated greater draining tunnel reductions versus placebo that were sustained or improved to Week 48...